IGF2BP1 and neoplasm: BTYNB disrupted IGF2BP1–mRNA binding and induced leukemic differentiation; more recently, IGF2BP1 blockade reduced YAP1 signaling and tumor growth, strengthening the case for the druggability of reader–RNA interfaces (151).